kansl3 Antibody

What is KANSL3 and why is it important in epigenetic research?

KANSL3 is a critical component of the KAT8 regulatory NSL (nonspecific lethal) complex involved in histone acetylation, particularly H4K16 acetylation. This protein plays a fundamental role in chromatin remodeling and transcriptional regulation of essential genes. Research shows that the NSL complex is required for expression of a subset of essential genes in human cells, with KANSL3 being instrumental in this process . Studies have demonstrated that KANSL3 occupies different sets of enhancers that are ES cell-specific and essential for maintaining stem cell identity .

Methodologically, to study KANSL3's epigenetic function, researchers have used chromatin immunoprecipitation sequencing (ChIP-seq) to identify KANSL3-specific peaks, which predominantly (77.2%) co-localize with H3K4me3 and are positioned at transcription start sites (TSSs) .

What are the main cellular localizations of KANSL3 across the cell cycle?

KANSL3 exhibits distinct localization patterns throughout the cell cycle:

• Interphase: Predominantly concentrated in the nucleus, consistent with its role in chromatin regulation and gene expression

• Mitosis: Undergoes marked relocalization to spindle poles throughout prometaphase, metaphase, and anaphase

This dual localization correlates with KANSL3's bifunctional roles: nuclear gene regulation during interphase and spindle pole-associated functions during cell division. Immunofluorescence microscopy using anti-KANSL3 antibodies with appropriate cell cycle markers is the recommended method for visualizing these distinct localizations .

Antibody Selection and Validation

Methodological approach for validating KANSL3 antibody specificity:

• Perform knockdown validation:

  • Use CRISPR interference (CRISPRi) rather than CRISPR knockout to avoid truncated or in-frame-modified protein products that might still be recognized by the antibody

  • Validate knockdown efficiency by western blot and RT-qPCR

  • Conduct immunofluorescence with and without knockdown to verify signal specificity

• Examine molecular weight correspondence:

  • Expected molecular weight is ~93-96 kDa calculated, but observed weight ranges from 105-120 kDa due to post-translational modifications

  • Validate antibody detection of KANSL3 in validated positive samples like U-251MG, Jurkat, or U2OS cells

• Test cross-reactivity:

  • If working with non-human models, verify species cross-reactivity as most antibodies are validated primarily for human KANSL3

What are the optimal protocols for using KANSL3 antibodies in immunofluorescence microscopy?

For optimal immunofluorescence microscopy using KANSL3 antibodies:

• Cell preparation:

  • Fix cells with 4% paraformaldehyde for 15 minutes at room temperature

  • Permeabilize with 0.1% Triton X-100 for 10 minutes

• Antibody incubation:

  • Block with 5% BSA in PBS for 1 hour

  • Incubate with primary anti-KANSL3 antibody at 1:50-1:500 dilution overnight at 4°C

  • Wash 3× with PBS

  • Incubate with appropriate fluorophore-conjugated secondary antibody

• Imaging considerations:

  • For cell cycle studies, co-stain with markers such as phospho-histone H3 (PH3) for mitosis

  • For spindle localization studies, co-stain with α-tubulin

  • For chromatin association studies, co-stain with DNA markers and H3K4me3

Research findings show that during mitosis, KANSL3 strongly enriches at spindle poles throughout all mitotic phases, which requires specific imaging settings to properly capture this dynamic localization .

How should I optimize Western blot protocols for KANSL3 detection?

For optimal Western blot detection of KANSL3:

• Sample preparation:

  • Use RIPA buffer with protease inhibitors

  • Include phosphatase inhibitors if studying post-translational modifications

• Gel electrophoresis and transfer:

  • Use 8-10% SDS-PAGE gels due to the high molecular weight of KANSL3

  • Transfer to PVDF membrane at low amperage (250mA) overnight at 4°C for efficient transfer of large proteins

• Antibody incubation:

  • Block with 5% non-fat milk in TBST

  • Recommended dilutions range from 1:1000 to 1:5000 for primary antibody

  • Consider using high sensitivity detection systems for low abundance samples

• Expected results:

  • Calculated molecular weight: 93-96 kDa

  • Observed molecular weight: 105-120 kDa (discrepancy likely due to post-translational modifications)

  • Validated positive controls include HEK-293, Jurkat, and U2OS cells

How can KANSL3 antibodies be used to study its dual role in chromatin regulation and mitotic spindle organization?

To investigate KANSL3's dual functionality:

• Chromatin association studies:

  • Perform ChIP-seq using KANSL3 antibodies to identify genomic binding sites

  • Research has shown KANSL3 peaks predominantly (77.2%) co-localize with H3K4me3 and localize to transcription start sites

  • Compare KANSL3 binding with other NSL complex members to identify unique and common targets

  • Combine with transcriptomic analysis following KANSL3 knockdown to identify regulated genes

• Mitotic function analysis:

  • Use synchronized cell populations to enrich for mitotic cells

  • Perform co-immunoprecipitation with KANSL3 antibodies to identify mitosis-specific interaction partners

  • Research shows KANSL3 interacts with TPX2 in a RanGTP-dependent manner, promoting microtubule assembly in vitro

  • Use live-cell imaging with fluorescently tagged KANSL3 antibodies to track dynamical changes during mitosis

• Structure-function investigations:

  • Use domain-specific antibodies to determine which regions of KANSL3 are responsible for different functions

  • Research indicates KANSL3 is an autonomous microtubule minus-end-binding protein, which targets other NSL complex members to K-fibre minus ends

How do genetic manipulations of KANSL3 affect histone acetylation patterns detectable by immunostaining?

Studies investigating KANSL3 knockout effects on histone acetylation have revealed:

• H4K5ac modification:

  • KANSL3 null mutant embryos show significant reduction in H4K5ac levels compared to controls

  • Immunofluorescence quantification of nuclear H4K5ac signal intensity provides a reliable readout of KANSL3 function

• Other histone acetylation marks:

  • No significant differences were observed in H4K8ac, H4K12ac, or H4K16ac in KANSL3 mutants

  • This suggests specificity in KANSL3's role in acetylation patterning

Methodological approach:

• Perform immunofluorescence with antibodies against multiple histone acetylation marks

• Quantify nuclear fluorescence intensity

• Normalize to total histone H4 or DAPI signal

• Compare wild-type vs. KANSL3-depleted conditions

These findings indicate that while KANSL3 is part of a complex known to catalyze H4K16 acetylation, its individual contribution may be more specific to H4K5 acetylation, suggesting a nuanced role within the NSL complex .

What experimental approaches using KANSL3 antibodies can help understand its role in embryonic development?

Methodological approaches for studying KANSL3 in development:

• Immunostaining of early embryos:

  • Use KANSL3 antibodies for immunofluorescence of pre-implantation embryos

  • Co-stain with lineage markers: NANOG (epiblast), SOX17 (primitive endoderm), and CDX2 (trophectoderm)

  • Quantify cell numbers in each lineage to assess KANSL3's role in cell fate determination

• Cell death and proliferation analysis:

  • Use TUNEL assay to detect apoptosis in KANSL3 mutant embryos

  • Immunostain for phospho-histone H3 to assess cell cycle progression

  • Research has shown no significant increase in TUNEL-positive cells or PH3-positive cells in KANSL3 null embryos, suggesting developmental defects are not due to cell death or cell cycle arrest

• In vitro outgrowth assays:

  • Culture blastocysts with or without zona pellucida removal

  • Monitor hatching and outgrowth formation

  • Research shows KANSL3 null embryos fail to hatch from zona pellucida and form abnormal outgrowths with disrupted ICM morphology

Research findings demonstrate that KANSL3 mutant embryos exhibit lineage-specific defects, with significantly reduced inner cell mass (ICM) cell numbers but no difference in trophectoderm cell numbers, indicating a specific role in ICM development .

What controls should be included when using KANSL3 antibodies for analyzing mitotic defects?

When analyzing mitotic defects using KANSL3 antibodies:

• Essential controls:

  • KANSL3 knockdown/knockout validation: Verify antibody specificity using KANSL3-depleted cells

  • Cell cycle synchronization validation: Confirm cell cycle stage using established markers

  • Co-staining controls: Include markers for mitotic stages (e.g., phospho-histone H3) and spindle structures (α-tubulin)

• Quantification approaches:

  • Measure mitotic index in control vs. KANSL3-depleted cells

  • Categorize mitotic defects (e.g., multipolar spindles, chromosome misalignment)

  • Quantify time spent in different mitotic phases using live cell imaging

• Functional validation:

  • Compare phenotypes with knockdown of other NSL complex members

  • Research shows KANSL1 knockdown causes more severe mitotic defects than KANSL3 knockdown, possibly because KANSL1 silencing destabilizes other NSL complex members

Research findings indicate that knockdown of KANSL3 results in marked mitotic defects, with 61% of cells entering mitosis unable to complete it during a 24-hour recording period . The most prevalent defect observed is prolonged arrest in a prometaphase-like state .

How can I address inconsistent KANSL3 antibody staining patterns in different cell types?

When encountering variable KANSL3 staining patterns:

• Cell type-specific considerations:

  • KANSL3 expression levels vary across cell types; adjust antibody concentration accordingly

  • Cell type-specific interactors may mask epitopes; test multiple antibodies targeting different regions

  • Fixation protocols may need optimization for specific cell types

• Technical troubleshooting:

  • Antigen retrieval: For IHC applications, test both TE buffer pH 9.0 and citrate buffer pH 6.0

  • Antibody dilution optimization: Test a range from 1:50 to 1:500 for IHC

  • Permeabilization: Adjust detergent type and concentration for different cell types

• Biological interpretation:

  • Cell cycle stage impacts KANSL3 localization, with nuclear staining in interphase and spindle pole localization during mitosis

  • Differentiation status may affect KANSL3 expression and localization, particularly in stem cells

How should I interpret discrepancies between predicted and observed molecular weights of KANSL3 in Western blots?

When addressing molecular weight discrepancies:

• Expected vs. observed weights:

  • Calculated molecular weight: 93-96 kDa

  • Observed molecular weight: 105-120 kDa

• Potential explanations:

  • Post-translational modifications, particularly phosphorylation during mitosis

  • Alternative splicing variants (ensure your antibody targets a conserved region)

  • Incomplete denaturation leading to persistent protein-protein interactions

  • SDS-resistant structural features affecting migration

• Validation approaches:

  • Test multiple antibodies targeting different epitopes

  • Use positive control lysates from cells known to express KANSL3 (e.g., U-251MG, Jurkat, U2OS)

  • Consider performing mass spectrometry analysis to confirm protein identity

  • Use protein dephosphorylation treatments to test if post-translational modifications explain the discrepancy

Research indicates that KANSL3 undergoes various modifications throughout the cell cycle, which likely explains the consistently higher observed molecular weight across multiple studies and antibodies .